Horizon Discovery

A gene editing company that designs and engineers genetically-modified cells. Learn more

Launch date

Jun 2005

Employees

201-500 people

Market cap

Enterprise valuation

CAD522m (Public information from Nov 2020)

Company register number 08921143

Cambridge England (HQ)

http://www.horizondiscovery.com/

https://twitter.com/horizongenomics https://www.facebook.com/pages/Horizon-Discovery/801774256513261 https://www.linkedin.com/company/horizon-discovery

Revenues, earnings & profits over time

EUR	2015	2016	2017	2018	2019	2020	2022
Revenues	29.0m	73.0m	132m	154m	185m	196m	-
% growth	-	152 %	81 %	17 %	21 %	6 %	-
EBITDA	(7.9m)	(10.0m)	(10.0m)	(40.0m)	(7.0m)	(14.4m)	(3.1m)
% EBITDA margin	(27 %)	(14 %)	(8 %)	(26 %)	(4 %)	(7 %)	-
Profit	-	7.0m	30.0m	48.2m	60.9m	65.5m	-
% profit margin	-	10 %	23 %	31 %	33 %	33 %	-

Date	Investors	Amount	Round
-	Telegraph Hill Partners healthtech.vc 2i3T	N/A	-
Apr 2008	University of Cambridge	$300k	Seed
Jan 2010	Eurostars SME programme	N/A	Grant
Sep 2010	Threshold Ventures David Evans Jonathan Milner Roche Venture Fund	$9.8m	Series A
Jul 2011	Eurostars SME programme	€300k	Grant
Sep 2011	N/A	£7.0m	Series B
Jan 2012	Molten Ventures Roche Venture Fund MVM Life Science Partners	$18.6m	Series C
Apr 2013	Tech Nation	N/A	Support Program
Jun 2013	Molten Ventures Calculus Capital David Evans Jonathan Milner Wren Capital Roche Venture Fund MVM Life Science Partners Parkwalk Advisors University of Cambridge	£6.9m	Series C
Mar 2014	N/A	£68.6m	IPO
Nov 2020	Perkinelmer Las (Uk) Limited	$383m Valuation: $383m 1.9x EV/LTM Revenues -49.7x EV/LTM EBITDA	Acquisition
Total Funding		CAD64.6m

Horizon Discovery specializes in gene editing and gene modulation technologies, serving academic institutions, pharmaceutical companies, biotechnology firms, and clinical diagnostic laboratories. The company operates in the life sciences market, providing tools and services that help identify genetic drivers of human diseases, develop diagnostic workflows, and create new therapies for precision medicine. Horizon Discovery's business model revolves around offering innovative products such as CRISPR design tools, siRNA, and custom RNA synthesis, as well as services like cell line engineering and in vivo screening. Revenue is generated through the sale of these products and services, catering to clients who require advanced genetic research capabilities.

Keywords: gene editing, gene modulation, CRISPR, siRNA, RNA synthesis, cell lines, precision medicine, biotechnology, diagnostics, life sciences.

Tech stackLearn more about the technologies and tools that this company uses.